<DOC>
	<DOCNO>NCT01341340</DOCNO>
	<brief_summary>The purpose ABSORB BTK Clinical Investigation evaluate safety efficacy Everolimus Eluting Bioresorbable Vascular Scaffold System ( BVS ) subject critical limb ischemia ( CLI ) follow percutaneous transluminal angioplasty ( PTA ) tibial artery .</brief_summary>
	<brief_title>The ABSORB BTK ( Below The Knee ) Clinical Investigation</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Subject must least 18 ≤ 80 year age . 2 . History symptomatic critical limb ischemia ( CLI ) ( Rutherford Becker Clinical Category 4 5 ) . 3 . Subject able take least one type thienopyridine ( e.g . clopidogrel ) acetylsalicylic acid ( eg . Aspirin/ASA ) . 4 . The subject must lifeexpectancy 1 year . 5 . Female subject childbearing potential must negative pregnancy test within 14 day treatment , must nursing time treatment , must also agree time consent use birth control participation study include angiographic followup 1 year . 6 . Subject informed nature study , agree provision , sign informed consent form prior study related procedure . 7 . Subject must agree undergo protocolrequired followup examination requirement investigational site . 8 . Subject must agree participate clinical investigation period one year follow index procedure . This include clinical trial medication invasive procedure . Questionnairebased study , study noninvasive require medication allow . Anatomic Inclusion Criteria 1 . Up two de novo lesion , locate separate native infrapopliteal vessel , angiographically visible abovetheankle reconstitution ( proximal inferior cortical margin talus bone ) , one designate target lesion suitable treat single BVS . 2 . Target lesion length visually estimate ≤ 24 mm . 3 . Target vessel diameter location target lesion ≥ 2.5 mm ≤ 3.3 mm , assess online quantitative angiography per core laboratory guideline . 4 . The nontarget lesion ( applicable ) must locate separate infrapopliteal vessel , estimate ≤ 24 mm , suitable treat nonstudy percutaneous transluminal angioplasty ( PTA ) balloon ( ) and/or nonstudy stent . 5 . Inflow proximal iliac distal popliteal unobstructed ( free ≥ 50 % stenosis ) confirm angiography . [ Note : Assessment may make intervention proximal target lesion . ] 6 . Subjects significant lesion ( ≥ 50 % stenosis ) inflow artery ( y ) must inflow artery ( y ) treat successfully prior enrollment treatment target lesion . 7 . If evidence ischemic lesion/ulcer foot , distribution target vessel must supply area lesion ( angiosome ) , confirm angiography . 8 . At least one patent distal tibial outflow artery ( &lt; 50 % stenosis ) provide straight line blood flow distal foot ( applicable ) wound area treat target lesion tibioperoneal trunk . 9 . Patent pedal outflow artery ( &lt; 50 % stenosis ) provide straight line blood flow distal foot ( applicable ) wound area . 1 . Subject unable understand unwilling cooperate study procedure . 2 . The subject mentally ill belongs vulnerable population . 3 . Subject currently breastfeed , pregnant , intend become pregnant prior completion 1 year angiographic followup . 4 . Subject type amputation ipsilateral contralateral extremity . 5 . Subject unable walk . ( assistance accept ) 6 . Subject recent major surgery ( require general regional anesthesia impact major organ system ) within last 3 month . 7 . Subject receive , wait list major organ transplant . 8 . Subject diagnose Rutherford Becker Clinical Category 0 , 1 , 2 , 3 6 . 9 . Subject type infection , treat successfully . 10 . Subject osteomyelitis present distal ipsilateral extremity . 11 . Subject history bleed diathesis coagulopathy refuse blood transfusion . 12 . The subject history prior lifethreatening contrast medium reaction . 13 . Subject receive schedule receive anticancer therapy malignancy within 1 year prior procedure . 14 . Subject receive immunosuppression therapy , know serious immunosuppressive disease ( e.g. , human immunodeficiency virus ) , severe autoimmune disease require chronic immunosuppressive therapy ( e.g. , systemic lupus erythematosus , etc. ) . 15 . Subject receive receive inhibitor CYP3A inducer CYP3A within 30 day prior follow procedure . 16 . Subject receive Phenprocoumon ( Marcumar ) schedule receive chronic anticoagulation therapy . 17 . Subject severe liver impairment define total bilirubin &gt; 3 mg/dl two time increase normal level serum glutamic oxaloacetic transminase ( SGOT ) serum glutamic pyruvic transminase ( SGPT ) . 18 . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , hemoglobin &lt; 10.0 g/dl . 19 . Subject elevate serum creatinine &gt; 2.0 mg/dl &gt; 150μmol/L . 20 . Subject uncontrolled diabetes mellitus ( DM ) ( glucose &gt; 400 mg/dl ) . 21 . Subject myocardial infarction ( MI ) within previous 30 day unstable angina ( define rest angina ECG change ) . 22 . Subject stroke within previous 30 day and/or deficit prior stroke limit subject 's mobility . 23 . Subject acute thrombophlebitis deep vein thrombosis either extremity 24 . Subject know allergy follow : aspirin , thienopyridines , heparin , contrast agent ( adequately treat premedication substitution alternate thienopyridine ) , poly ( Llactide ) , poly ( DLlactide ) , drug similar everolimus ( i.e . tacrolimus , sirolimus , zotarolimus ) , macrolides . 25 . Subject require planned procedure would necessitate discontinuation thienopyridines follow procedure . If subject enrol study require medical procedure , would necessitate discontinuation medication , subject resume protocol recommend medication soon possible . 26 . Subject know medical illness ( e.g. , cancer congestive heart failure ) may cause subject noncompliant protocol requirement , confound data interpretation , associate limited lifeexpectancy ( i.e. , less 1 year ) . 27 . Subject already participate another clinical investigation yet reach primary endpoint . Anatomic Exclusion Criteria 1 . The target lesion access via popliteal pedal approach . 2 . The target vessel diameter location target lesion suitable available BVS size . 3 . Unsuccessfully treat proximal inflow limit arterial stenosis inflowlimiting arterial lesion leave untreated . 4 . No angiographic evidence patent pedal artery . 5 . Significant ( &gt; 50 % stenosis ) lesion distal outflow artery require treatment time index procedure . 6 . More single significant lesion ( &gt; 50 % stenosis ) target vessel . 7 . Target ( applicable ) nontarget lesion location require bifurcation treatment method . 8 . Target ( applicable ) nontarget lesion lie within adjacent aneurysm . 9 . A segment/portion study scaffold deploy distal inferior cortical margin talus bone pedal vessel . 10 . Subject previously , require , bypass surgery , endarterectomy vascular surgery vessel ipsilateral extremity . 11 . Subject moderate severe calcium target lesion artery immediately adjacent target lesion , investigator unable predilate lesion accord vessel diameter . 12 . Target ( applicable ) nontarget vessel contain visible thrombus indicate angiographic image . 13 . Subject angiographic evidence thromboembolism atheroembolism ipsilateral extremity . ( Pre postangiographic image must confirm absence emboli distal anatomy . ) 14 . Target ( applicable ) nontarget lesion high probability procedure predilatation , implantation scaffold , postdilatation ( applicable ) require time index procedure treatment target vessel ( e.g. , atherectomy , cut balloon , etc. ) . 15 . Subject lesion target vessel treated require treatment &lt; 1 year preor post study procedure . 16 . Subject lesion vascular anatomy , treat time study procedure , treat require treatment &lt; 30 day preor post study procedure . 17 . Subject require treatment drugeluting/coated stent drugcoated balloon vessel &lt; 90 day preor poststudy procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Stent</keyword>
	<keyword>Infrapopliteal</keyword>
	<keyword>Tibial</keyword>
	<keyword>Limb Salvage</keyword>
</DOC>